BLOG

Fierce-Biotech

Tvardi snags $74M to weed the tumor garden with STAT3 inhibitor

The clinical-stage biopharma unveiled the $74 million series B financing Wednesday, brought in from new investors Slate Path Capital, Palkon Capital, ArrowMark Partners and 683 Capital on top of existing backers like Sporos Bioventures.